Oncotarget

Research Papers:

Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival

Elisabetta Panza, Paola De Cicco, Giuseppe Ercolano, Chiara Armogida, Giosuè Scognamiglio, Anna Maria Anniciello, Gerardo Botti, Giuseppe Cirino _ and Angela Ianaro

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:57077-57085. https://doi.org/10.18632/oncotarget.10976

Metrics: PDF 606 views  |   HTML 1027 views  |   ?  


Abstract

Elisabetta Panza1,*, Paola De Cicco1,*, Giuseppe Ercolano1, Chiara Armogida1, Giosuè Scognamiglio2, Anna Maria Anniciello2, Gerardo Botti2, Giuseppe Cirino1, Angela Ianaro1

1Department of Pharmacy, University of Naples Federico II, Naples Italy

2Department of Experimental Oncology, National Cancer Institute, G. Pascale, Naples, Italy

*These authors have contributed equally to this work

Correspondence to:

Giuseppe Cirino, email: cirino@unina.it

Keywords: malignant melanoma, cyclooxygenase-2, COX-2-/- mice, progression free survival, metastasis

Received: April 11, 2016    Accepted: July 19, 2016    Published: August 01, 2016

ABSTRACT

The possible correlation between cyclooxygenase-2 (COX-2) expression and disease progression in melanoma is still a matter of debate. Analysis of COX-2 expression in 45 lymph node melanoma metastases demonstrates a significant correlation between the percent of expression and progression free survival (PFS). A positive COX-2 expression ≥10% (COX-2high), as opposite to a positive expression ≤9% (COX-2low), translated into a striking significant reduction of PFS of about 3 years. The reduction in PFS correlated neither with BRAFV600E nor with NRASQ61 expression in the analyzed samples. This concept was reinforced by the finding that tumour development in COX-2-/- mice was almost blunted. Similarly, inhibition of COX-2 protein expression in human melanoma cell lines, by using siRNAs technology as well as selective inhibition of COX-2 activity by celecoxib, reduced cellular proliferation and invasiveness. In conclusion we show that COX-2high is a negative prognostic factor in metastatic melanoma. Our study also clarifies that the uncertainty about the role of COX-2 in metastatic malignant melanoma, found in the current relevant literature, is probably due to the fact that a threshold in COX-2 expression has to be reached in order to impact on cancer malignancy. Our findings suggest that COX-2 expression may become an useful diagnostic tool in defining melanoma malignancy as well as argue for a possible therapeutic use of NSAID as add on therapy in selected cases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10976